多发性骨髓瘤中的嵌合抗原受体T细胞与双特异性抗体治疗:迈向未来
本综述分析已获批的靶向B细胞成熟抗原(BCMA)的CAR T细胞疗法(idecabtagene vicleucel和ciltacabtagene autoleucel)及BCMA/CD3双特异性抗体(teclistamab)用于晚期复发/难治多发性骨髓瘤的数据,并概述其他在研CAR T细胞和双特异性抗体疗法,讨论疗效、安全性(细胞因子释放综合征、神经毒性、感染风险)、优化序贯与支持治疗及公平可及性等未满足需求。
要点
- 已获批的BCMA靶向CAR T细胞和BCMA/CD3双特异性抗体在重度复发/难治多发性骨髓瘤中产生前所未有的缓解率和缓解持续时间。
- 美国已批准两种BCMA CAR T细胞疗法和一种BCMA/CD3双特异性抗体用于既往接受超过四线治疗的复发/难治多发性骨髓瘤。
- 关注细胞因子释放综合征、神经毒性和感染风险,以及优化序贯和支持治疗、确保公平可及等未满足需求。
核心结论
- CAR T细胞和双特异性抗体疗法将改变多发性骨髓瘤的治疗范式,但仍有大量工作需确定这些新疗法的最佳使用并确保公平可及。
研究设计与样本
- 综述,分析已获批及在研的CAR T细胞和双特异性抗体疗法的近期数据。
主要发现
- 在重度复发/难治人群中,CAR T细胞和T细胞重定向双特异性抗体疗法产生前所未有的缓解率和缓解持续时间。
- 美国已批准两种BCMA靶向CAR T细胞疗法(idecabtagene vicleucel和ciltacabtagene autoleucel)及一种BCMA/CD3双特异性抗体(teclistamab)用于既往接受超过四线治疗的复发/难治多发性骨髓瘤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple myeloma (MM) have been poor because of a dearth of effective treatment options. However, the advent of chimeric antigen receptor (CAR) T-cell and T-cell redirecting bispecific antibody (BsAb) therapies has led to unprecedented response rates and durations of response in heavily relapsed/refractory (R/R) populations. Currently, two B-cell maturation antigen (BCMA)-directed CAR T-cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) as well as one BCMA/CD3 BsAb (teclistamab) have been approved for late-line (greater than four previous lines) R/R MM in the United States. The purpose of this review is to analyze the recent data for these approved therapies as well as provide an overview of other related CAR T-cell and BsAb therapies under development, including non-BCMA-targeting agents. We review efficacy and safety considerations, with particular focus on cytokine release syndrome, neurotoxicity, and infection risk. The relative merits and limitations of each class of therapy are discussed, as well as the areas of unmet need with respect to optimal sequencing and supportive care measures. We examine the factors that challenge equitable access to these novel therapies across minoritized racial, ethnic, and socioeconomic populations. Although it is evident that CAR T-cell and BsAb therapies will transform treatment paradigms in MM for years to come, significant work remains to identify the optimal utilization of these novel therapies and ensure equitable access.
引用
- Holstein SA, Grant SJ, Wildes TM, et al. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future. J Clin Oncol. 2023. PMID: 37471687. doi:10.1200/JCO.23.00512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。